Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense to Present in vivo Cellular Imaging Technology at AACR as Potential Tool in Treatment of Cancer

Fluorine-based cell imaging label shown effective in MRI-NMR post-injection detection and quantification of various immunotherapy cell types

Pittsburgh, PA (April 9, 2009) - Celsense, Inc. announced today that one of its Research Scientists, Brooke M. Helfer, Ph.D. , will present cellular imaging data from its lead compound (Cell Sense) at the AACR (American Association for Cancer Research) conference to be held April 18-22 in Denver, CO. 

The study shows the use of a novel fluorine-based (19F) MRI tracer agent (Cell Sense) to label multiple, clinically relevant human immune cells ex vivo without a transfection reagent.  Several phagocytic and nonphagocytic cell types including natural killer cells (NK), T cells and dendritic cells (DC) were all labeled without any evidence of toxicity or altered proliferative characteristics.

The labeled cells were then imaged by MRI in vivo after injection and, by pairing the 19F MR image with conventional 1H MRI taken during the same MRI session, images allowed clear cell localized detection and quantification within an image providing anatomic context.

Research for the study was conducted by scientists at Carnegie Mellon University, University of Pittsburgh, and the Nijmegen Center for Molecular Life Sciences.

Cell therapy is one field of research aiming to target and destroy cancer cells.  A current limitation of cell therapy is the inability to track the movement of these cells once they are administered to a patient.  By facilitating non-invasive visual specificity of 19F labeled cells provided by MRI, the Cell Sense technology may prove to be a useful clinical tool in the application of cell therapy in the treatment of cancer. 

About Cell Sense—Cell Sense is a fluorocarbon tracer agent used to label cells in vitro then transplanted thus enabling investigators and clinicians to noninvasively track the administration and delivery of therapeutic and diagnostic cells in vivo using MRI.  Applications include tracking therapeutic cells in regenerative medicine and immunotherapy applications, and observing localized immune system response by tracking populations of immune system cells.  Using software developed by Celsense, the investigators can quantify the number of labeled cells in a user-specified region of interest.

About Celsense, Inc.—Celsense, Inc. (the “Company” and “Celsense”) is an emerging biotechnology company offering novel pre-clinical and clinical-grade molecular imaging agents used to non-invasively visualize and measure biological processes at the cellular level in living systems. The core innovations of the Company involve molecular imaging agents that can be used to observe the trafficking of cells in small or large animals including humans using magnetic resonance techniques. The mission of the Company is to establish Celsense as the standard for cellular and molecular imaging in human health research and therapeutics.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com